Immunic presents additional Phase 2 CALLIPER data for vidofludimus calcium in progressive MS at CMSC 2026

IMMUNIC, INC.

Late-breaking poster introduces novel unified endpoint Confirmed Disability Change (CDC) that consistently favored vidofludimus calcium over placebo across three statistical models.
Patient-reported outcomes (PHQ-9) showed no worsening of depressive or suicidal thoughts; treatment satisfaction numerically favored drug over placebo at weeks 48 and 120.
Safety data from 467 patients: TEAEs comparable (69.4% vs 68.5%), discontinuation due to TEAEs identical at 2.6% in both arms; no Hy's law cases.
Serious adverse events low and balanced (8.1% vs 6.5%); liver-related TEAEs similar (5.2% vs 5.5%).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.